{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:34:52Z","timestamp":1773772492320,"version":"3.50.1"},"reference-count":22,"publisher":"Pleiades Publishing Ltd","issue":"1","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dokl Biochem Biophys"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1134\/s1607672924701151","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T06:02:28Z","timestamp":1730354548000},"page":"525-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Study of the Comparability of the Pharmacodynamic, Toxicological, and Pharmacokinetic Properties of the Reference Drug Pulmozyme\u00ae and the Biosimilar Drug Tigerase\u00ae"],"prefix":"10.1134","volume":"519","author":[{"given":"M. S.","family":"Aksenova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. N.","family":"Bocharova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. G.","family":"Abbasova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. S.","family":"Ponomarev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. V.","family":"Loginova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. V.","family":"Bolotnikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. V.","family":"Belskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"Kazarov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. E.","family":"Lisova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. K.","family":"Kudina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. S.","family":"Pantyushenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. V.","family":"Zhilyaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. S.","family":"Kopein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu. M.","family":"Karelov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. G.","family":"Erastov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. V.","family":"Lykov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. A.","family":"Khamitov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"7620_CR1","first-page":"20","volume":"6","author":"S.N. Avdeev","year":"2007","unstructured":"Avdeev, S.N., Avdeeva, O.E., and Chuchalin, A.G., Exogenous allergic alveolitis, Russ. Med. Zh., 2007, vol.\u00a06, pp. 20\u201332.","journal-title":"Russ. Med. Zh."},{"key":"7620_CR2","unstructured":"Klinicheskie rekomendatsii. Kistoznyi fibroz (mukovistsidoz) (Clinical Guidelines: Cystic Fibrosis (Mucoviscidosis)), 2020."},{"key":"7620_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.37489\/2588-0519-2020-5-38-49","volume":"5","author":"A.S. Kolbin","year":"2020","unstructured":"Kolbin, A.S., Gomon, Yu.M., Karpov, O.I., Balykina, Yu.E., and Proskurin, M.A., Cystic fibrosis as a socio-economic problem, Kach. Klin. Prakt., 2020, vol. 5, pp.\u00a038\u201349. https:\/\/doi.org\/10.37489\/2588-0519-2020-5-38-49","journal-title":"Kach. Klin. Prakt."},{"key":"7620_CR4","first-page":"388","volume":"7","author":"V.V. Kosarev","year":"2013","unstructured":"Kosarev, V.V. and Babanov, S.A., Exogenous allergic alveolitis: diagnostic problems, Ross. Med. Zh., 2013, vol. 7, pp. 388\u2013392.","journal-title":"Ross. Med. Zh."},{"key":"7620_CR5","first-page":"21","volume":"3","author":"A.A. Lidzhieva","year":"2015","unstructured":"Lidzhieva, A.A., Smolyarchuk, E.A., and El\u2019tsova, E.A., Biosimilars\u2014advantages and prospects, Biopreparaty, 2015, vol. 3, pp. 21\u201324.","journal-title":"Biopreparaty"},{"key":"7620_CR6","unstructured":"Mezhdunarodnaya klassifikatsiya boleznei 10-go peresmotra (International Classification of Diseases 10th Revision (ICD-10)). https:\/\/mkb-10.com\/."},{"key":"7620_CR7","unstructured":"Registr bol\u2019nykh mukovistsidozom v Rossiiskoi Federatsii (Register of Cystic Fibrosis Patients in the Russian Federation), 2019."},{"key":"7620_CR8","doi-asserted-by":"publisher","unstructured":"Cooney, A., Mccray, P., and Sinn, P., Cystic fibrosis gene therapy: looking back, looking forward, Genes (Basel), 2018, vol. 9, no. 11, pp. 538\u2013561. https:\/\/doi.org\/10.3390\/genes9110538","DOI":"10.3390\/genes9110538"},{"key":"7620_CR9","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1177\/096032719401300101","volume":"13","author":"A.D. Dayan","year":"1994","unstructured":"Dayan, A.D., Pharmacological-toxicological (expert report on recombinant human deoxyribonuclease I (rhDNase, Pulmozyme\u2122), Hum. Exp. Toxicol., 1994, vol. 13, no. 1 (Suppl.), pp. S2\u2013S42. https:\/\/doi.org\/10.1177\/096032719401300101","journal-title":"Hum. Exp. Toxicol."},{"key":"7620_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.21037\/atm.2018.06.48","volume":"6","author":"M.C. Dechecchi","year":"2018","unstructured":"Dechecchi, M.C., Tamanini, A., and Cabrini, G., Molecular basis of cystic fibrosis: from bench to bedside, Ann. Transl. Med., 2018, vol. 6, no. 17, p. 334. https:\/\/doi.org\/10.21037\/atm.2018.06.48","journal-title":"Ann. Transl. Med."},{"key":"7620_CR11","doi-asserted-by":"publisher","unstructured":"Eisenberg, J.D., Aitken, M.L., Dorkin, H.L., Harwood, I.R., Ramsey, B.W., Schidlow, D.V., Wilmott, R.W., Wohl, M.E., Fuchs, H.J., Christiansen, D.H., and Smith, A.L., Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis, J. Pediatr., 1997, vol. 131, no. 1 (Pt. 1), pp. 118\u2013124. https:\/\/doi.org\/10.1016\/s0022-3476(97)70134-3","DOI":"10.1016\/s0022-3476(97)70134-3"},{"key":"7620_CR12","doi-asserted-by":"publisher","unstructured":"El-Bakry, L., The future of biosimilars, Int. J. Drug Delivery, 2017, vol. 9, no. 1, pp. 01\u201302. https:\/\/doi.org\/10.5138\/09750215.1930","DOI":"10.5138\/09750215.1930"},{"key":"7620_CR13","unstructured":"EMEA\/CHMP\/EWP\/192217\/2009 Rev. 1 Corr. 2. Guideline on Bioanalytical Method Validation, European Medicines Agency, Committee for Medicinal Products for Human Use, 2011."},{"key":"7620_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10198-013-0538-4","volume":"15","author":"M.-I. Farfan-Portet","year":"2014","unstructured":"Farfan-Portet, M.-I., Gerkens, S., Lepage-Nefkens, I., Vinck, I., and Hulstaert, F., Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?, Eur. J. Health Econ., 2014, vol. 15, pp.\u00a0223\u2013228.","journal-title":"Eur. J. Health Econ."},{"key":"7620_CR15","unstructured":"Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues (Revision 1), EMA\/CHMP\/ BWP\/247713\/2012, 2012. \nhttps:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins_en-0.pdf."},{"key":"7620_CR16","unstructured":"Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies\u2014Non-Clinical and Clinical Issues, CHMP\/BMWP\/403543\/2010, 2010. \nhttps:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf."},{"key":"7620_CR17","unstructured":"Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Drug Substance: Non-Clinical and Clinical Issues, EMEA\/ CHMP\/BMWP\/42832\/2005 Rev.\u00a01, 2005. \nhttps:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf."},{"key":"7620_CR18","doi-asserted-by":"publisher","unstructured":"Hodson, M.E., Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis, Am. J. Respir. Crit. Care Med., 1995, vol. 151, no. 3 (Pt. 2), pp. S70\u2013S74. https:\/\/doi.org\/10.1164\/ajrccm\/151.3_Pt_2.S70","DOI":"10.1164\/ajrccm\/151.3_Pt_2.S70"},{"key":"7620_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4103\/ijo.ijo_150_21","volume":"69","author":"S.G. Honavar","year":"2021","unstructured":"Honavar, S.G., From biologics to biosimilars and biobetters\u2014democratization of high-end therapeutics, Indian J. Ophthalmol., 2021, vol. 69, no. 2, pp. 207\u2013208. https:\/\/doi.org\/10.4103\/ijo.ijo_150_21","journal-title":"Indian J. Ophthalmol."},{"key":"7620_CR20","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3389\/fphar.2018.01475","volume":"9","author":"A. Semaniakou","year":"2018","unstructured":"Semaniakou, A., Croll, R.P., and Chappe, V., Animal models in the pathophysiology of cystic fibrosis, Front. Pharmacol., 2018, vol. 9, p. 1475. https:\/\/doi.org\/10.3389\/fphar.2018.01475","journal-title":"Front. Pharmacol."},{"key":"7620_CR21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","volume":"48","author":"G. Shankar","year":"2008","unstructured":"Shankar, G., Devanarayan, V., Amaravadi, L., Barrett, Yu.Ch., Bowsher, R., Finco-Kent, D., Fiscella, M., Gorovits, B., Kirschner, S., Moxness, M., Parish, T., Quarmby, V., Smith, H., Smith, W., Zuckerman, L.A., and Koren, E., Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products, J. Pharm. Biomed. Anal., 2008, vol. 48, no. 5, pp. 1267\u20131281. https:\/\/doi.org\/10.1016\/j.jpba.2008.09.020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"7620_CR22","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","volume":"73","author":"M.J. Welsh","year":"1993","unstructured":"Welsh, M.J. and Smith, A.E., Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis, Cell, 1993, vol. 73, no. 7, pp. 1251\u20131254. https:\/\/doi.org\/10.1016\/0092-8674(93)90353-R","journal-title":"Cell"}],"container-title":["Doklady Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672924701151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S1607672924701151","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672924701151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:18:53Z","timestamp":1773760733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S1607672924701151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7620"],"URL":"https:\/\/doi.org\/10.1134\/s1607672924701151","relation":{},"ISSN":["1607-6729","1608-3091"],"issn-type":[{"value":"1607-6729","type":"print"},{"value":"1608-3091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"When conducting experiments with animals, all provisions of the \u201cPolicy for Working with Laboratory Animals of the Testing Center of the Preclinical Research Center of JSC GENERIUM, based on the main international standards \"Directive 2010\/63\/EU of the European Parliament\u201d and of the Council of 22.09.2010 \u201cOn the Protection of Animals used for Scientific Purposes\u201d, and Appendix A to the \u201cEuropean Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes\u201d (ETS No. 123), were observed. Guidelines for the Care and Maintenance of Laboratory Animals (Article no. 5 of the Convention). The main conditions for keeping and handling animals, taking into account the \u201cThree R\u201d concept, were set out in the veterinary protocol, which was reviewed and approved by the Bioethics Commission of JSC GENERIUM (Minutes of the meeting of the Bioethics Commission No. 28\/2014 dated October 17, 2014). No deviations from the veterinary protocol were found during the experiments. The authors confirm that the established ethical norms and standards for working with animals were observed during the experiments using animals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}},{"value":"The authors of this work declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"CONFLICT OF INTEREST"}}]}}